<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The same research group in 2015 extended the scope of the clinical trial and the number of participants [
 <xref rid="B419-molecules-24-01364" ref-type="bibr" class="xref">419</xref>]. The secondary outcomes enriched by several parameters including genomic and neuroimaging techniques. A bi-center, 18 weeks, randomized, double blind, placebo-controlled phase III study were designed. 210 currently anxious participants with diagnosed GAD who were non-medicated were administered with aqueous extract of kava (standardized to deliver 240 mg of kavalactones per day) or placebo. The trial has been completed by 2018. However, the results of this study have not been released yet.
</p>
